β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells

  1. Noriyuki Sonoda,
  2. Takeshi Imamura,
  3. Takeshi Yoshizaki,
  4. Jennie L. Babendure,
  5. Juu-Chin Lu, and
  6. Jerrold M. Olefsky*
  1. Department of Medicine, Division of Endocrinology and Metabolism, University of California at San Diego, La Jolla, CA 92093
  1. Edited by Robert J. Lefkowitz, Duke University Medical Center, Durham, NC, and approved February 29, 2008 (received for review November 1, 2007)

Abstract

Glucagon-like peptide-1 (GLP-1) is a polypeptide hormone secreted from enteroendocrine L cells and potentiates glucose-dependent insulin secretion in pancreatic β cells. Recently the GLP-1 receptor (GLP-1 R) has been a focus for new anti-diabetic therapy with the introduction of GLP-1 analogues and DPP-IV inhibitors, and this has stimulated additional interest in the mechanisms of GLP-1 signaling. Here we identify a mechanism for GLP-1 action, showing that the scaffold protein β-arrestin-1 mediates the effects of GLP-1 to stimulate cAMP production and insulin secretion in β cells. Using a coimmunoprecipitation technique, we also found a physical association between the GLP-1 R and β-arrestin-1 in cultured INS-1 pancreatic β cells. β-Arrestin-1 knockdown broadly attenuated GLP-1 signaling, causing decreased ERK and CREB activation and IRS-2 expression as well as reduced cAMP levels and impaired insulin secretion. However, β-arrestin-1 knockdown did not affect GLP-1 R surface expression and ligand-induced GLP-1 R internalization/desensitization. Taken together, these studies indicate that β-arrestin-1 plays a role in GLP-1 signaling leading to insulin secretion, defining a previously undescribed mechanism for GLP-1 action.

Footnotes

  • *To whom correspondence should be addressed at:
    Department of Medicine (0673), University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0673.
    E-mail: jolefsky{at}ucsd.edu
  • Author contributions: N.S., T.I., and J.M.O. designed research; N.S., T.I., T.Y., J.L.B., and J.-C.L. performed research; N.S., T.I., and J.M.O. analyzed data; and N.S., T.I., and J.M.O. wrote the paper.

  • J.M.O. is a consultant for Pfizer Incorporated.

  • This article is a PNAS Direct Submission.

  • This article contains supporting information online at www.pnas.org/cgi/content/full/0710402105/DCSupplemental.

« Previous | Next Article »Table of Contents